Literature DB >> 28448699

Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder.

Carolyn I Rodriguez1,2,3, Kyle A B Lapidus4, Jordana Zwerling2, Amand Levinson5, Amanda Mahnke2, Shari A Steinman6, Eyal Kalanthroff7, Helen Blair Simpson8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28448699     DOI： 10.4088/JCP.16cr11234

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  3 in total

Review 1.  Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.

Authors:  Reilly R Kayser
Journal:  J Clin Psychiatry       Date:  2020-09-08       Impact factor: 4.384

2.  Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Brian P Brennan; Lorrin Koran; Carol A Mathews; Gerald Nestadt; Michele Pato; Katharine A Phillips; Carolyn I Rodriguez; H Blair Simpson; Petros Skapinakis; Dan J Stein; Eric A Storch
Journal:  Psychiatry Res       Date:  2021-03-04       Impact factor: 11.225

3.  Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.

Authors:  Giovanni Martinotti; Stefania Chiappini; Mauro Pettorruso; Alessio Mosca; Andrea Miuli; Francesco Di Carlo; Giacomo D'Andrea; Roberta Collevecchio; Ilenia Di Muzio; Stefano L Sensi; Massimo Di Giannantonio
Journal:  Brain Sci       Date:  2021-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.